An efficient hybrid differential evolution-golden jackal optimization algorithm for multilevel thresholding image segmentation.

Image segmentation is a crucial process in the field of image processing. Multilevel threshold segmentation is an effective image segmentation method, where an image is segmented into different regions based on multilevel thresholds for information analysis. However, the complexity of multilevel thresholding increases dramatically as the number of thresholds increases. To address this challenge, this article proposes a novel hybrid algorithm, termed differential evolution-golden jackal optimizer (DEGJO), for multilevel thresholding image segmentation using the minimum cross-entropy (MCE) as a fitness function. The DE algorithm is combined with the GJO algorithm for iterative updating of position, which enhances the search capacity of the GJO algorithm. The performance of the DEGJO algorithm is assessed on the CEC2021 benchmark function and compared with state-of-the-art optimization algorithms. Additionally, the efficacy of the proposed algorithm is evaluated by performing multilevel segmentation experiments on benchmark images. The experimental results demonstrate that the DEGJO algorithm achieves superior performance in terms of fitness values compared to other metaheuristic algorithms. Moreover, it also yields good results in quantitative performance metrics such as peak signal-to-noise ratio (PSNR), structural similarity index (SSIM), and feature similarity index (FSIM) measurements.

A novel TAB2 nonsense mutation (p.S149X) causing autosomal dominant congenital heart defects: a case report of a Chinese family.

BACKGROUND: TAB2 is an activator of MAP 3 K7/TAK1, which is required for the IL-1 induced signal pathway. Microdeletions encompassing TAB2 have been detected in various patients with congenital heart defects (CHD), indicating that haploinsufficiency of TAB2 causes CHD. To date, seven variants within TAB2 were reported associated with CHD, only two of them are nonsense mutations. CASE PRESENTATION: Here we describe a three-generation Chinese family that included five CHD patients with heart valvular defects, such as mitral or tricuspid valves prolapse or regurgitation, and aortic valve stenosis or regurgitation. Our proband was a pregnant woman presenting with mitral, tricuspid, and aortic defects; her first child experienced sudden cardiac death at the age of 2 years. Whole-exome sequencing of the proband revealed a novel nonsense variant in TAB2 (c.C446G, p.S149X), which results in the elimination of the majority of C-terminal amino acids of TAB2, including the critical TAK1-binding domain. The variant was identified in five affected patients but not in the eight unaffected family members using Sanger sequencing and was classified as "pathogenic" according to the latest recommendation on sequence variants laid out by the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. CONCLUSION: We described a family with CHD caused by a novel TAB2 nonsense mutation. Our study broadens the mutation spectrum of TAB2; to the best of our knowledge, this is the first report of a pathogenic mutation within TAB2 in a Chinese population.

Survival analysis of patients with advanced-stage nasopharyngeal carcinoma according to the Epstein-Barr virus status.

PURPOSE: The main aim of this study is to analyze the prognostic differences in nasopharyngeal carcinoma (NPC) patients who are positive and negative for Epstein-Barr virus (EBV). RESULTS: Of the 1106 patients, 248 (22.4%) had undetectable pre-treatment plasma EBV DNA levels. The total distant metastasis rate for EBV-negative group vs. EBV-positive group were 3.6% (9/248) vs. 15.0% (128/858) (P < 0.001). The estimated 4-year disease-free survival (DFS), overall survival (OS), distant metastasis-free survival (DMFS) and locoregional relapse-free survival (LRRFS) for EBV-negative group vs. EBV-positive group were 88.9% vs. 76.9% (P < 0.001), 93.6% vs. 85.9% (P = 0.001), 96.7% vs. 84.8% (P < 0.001) and 94.1% vs. 90.0% (P = 0.1), respectively. Multivariate analysis revealed that the EBV status was an independent prognostic factor for DFS (HR, 1.813; 95% CI, 1.219-2.695; P = 0.003), OS (HR, 1.828; 95% CI, 1.075-3.107; P = 0.026) and DMFS (HR, 3.678; 95% CI, 1.859-7.277; P <0.001), and overall stage still remained the most important prognostic factor in patients with stage III-IVB NPC. METHODS AND MATERIALS: Data on 1106 patients with non-metastatic, histologically proven advanced-stage (III-IVB) NPC who underwent intensity-modulated radiotherapy (IMRT) were retrospectively reviewed. Patient survival between different EBV status groups were compared. CONCLUSIONS: EBV status was an independent prognostic factor for patients with stage III-IVB NPC. Neoadjuvant chemotherapy (NCT) plus concurrent chemoradiotherapy (CCRT) should be better treatment regimen for EBV-positive patients since distant metastasis was the main failure pattern, and CCRT may be enough for EBV-negative patients.